The Endocannabinoid Reuptake Inhibitor WOBE437 Is Orally Bioavailable and Exerts Indirect Polypharmacological Effects via Different Endocannabinoid Receptors

Frontiers in Molecular Neuroscience - Switzerland
doi 10.3389/fnmol.2018.00180
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Frontiers Media SA

Related search

Endocannabinoid Tone Versus Constitutive Activity of Cannabinoid Receptors

British Journal of Pharmacology
Pharmacology
2011English

Endocannabinoid Turnover

Advances in Pharmacology
2017English

Total Synthesis of the Endocannabinoid Uptake Inhibitor Guineensine and SAR Studies

ChemMedChem
Organic ChemistryMolecular MedicinePharmacologyBiochemistryToxicologyDrug DiscoveryPharmaceutics
2019English

Inhibitor of Endocannabinoid Deactivation Protects Against in Vitro and in Vivo Neurotoxic Effects of Paraoxon

Journal of Molecular Neuroscience
MedicineMolecular NeuroscienceCellular
2017English

Cardiovascular Risk and the Endocannabinoid System

Kansas Journal of Medicine
2008English

Inhibition of COX-2 Expression by Endocannabinoid 2-Arachidonoylglycerol Is Mediated via PPAR-γ

British Journal of Pharmacology
Pharmacology
2011English

Potential Combinations of Endocannabinoid/Endocannabinoid-Like Compounds and Antibiotics Against Methicillin-Resistant Staphylococcus Aureus

PLoS ONE
Multidisciplinary
2020English

Endocannabinoid Signaling and Synaptic Function

Neuron
Neuroscience
2012English

Endocannabinoid Involvement in Endometriosis

Pain
NeurologyAnesthesiologyPain MedicinePharmacology
2010English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy